Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $34.00 Price Target at JPMorgan Chase & Co.

Day One Biopharmaceuticals (NASDAQ:DAWN) had its target price decreased by JPMorgan Chase & Co. from $39.00 to $34.00 in a report published on Wednesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other research firms have also weighed in on DAWN. Wedbush reaffirmed an “outperform” rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Bank of America dropped their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. The Goldman Sachs Group lowered their price target on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a report on Monday, February 10th. Finally, HC Wainwright lowered their price target on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of “Buy” and an average target price of $34.57.

Day One Biopharmaceuticals Stock Up 12.8 %

Shares of DAWN opened at $9.70 on Wednesday. The stock has a market cap of $983.14 million, a price-to-earnings ratio of -9.42 and a beta of -1.46. Day One Biopharmaceuticals has a 12 month low of $8.02 and a 12 month high of $18.07. The company has a 50-day moving average price of $11.93 and a two-hundred day moving average price of $13.27.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to the consensus estimate of $27.11 million. Equities research analysts expect that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the completion of the sale, the insider now owns 1,034,015 shares of the company’s stock, valued at approximately $13,762,739.65. The trade was a 2.82 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeremy Bender sold 12,048 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares of the company’s stock, valued at $1,531,059.40. This represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,064 shares of company stock valued at $651,225. Company insiders own 8.40% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

A number of institutional investors have recently bought and sold shares of DAWN. Mirae Asset Global Investments Co. Ltd. grew its holdings in Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after acquiring an additional 1,002 shares during the period. TimesSquare Capital Management LLC boosted its position in shares of Day One Biopharmaceuticals by 8.2% during the third quarter. TimesSquare Capital Management LLC now owns 1,827,695 shares of the company’s stock worth $25,460,000 after purchasing an additional 139,160 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Day One Biopharmaceuticals during the third quarter worth $825,000. Quest Partners LLC boosted its position in shares of Day One Biopharmaceuticals by 9,238.6% during the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after purchasing an additional 7,668 shares in the last quarter. Finally, First Turn Management LLC bought a new position in shares of Day One Biopharmaceuticals during the third quarter worth $13,204,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.